Article Text

PDF

Clinical and research medicine: Interventional cardiology
e0484 The safety study of tirofiban in patients with STEMI during emergency PCI
  1. Guo Lai-jing,
  2. Hu Dayi,
  3. Huo Yong,
  4. Tang Qiang,
  5. Zhang Huiying,
  6. Xing Liying,
  7. Wang Zhi,
  8. Zhang Shuhe,
  9. Shi Zhentao,
  10. Zhu Zhenzhong
  1. Chronic Disease Institute, Beijing University Shougang Hospital

Abstract

Objective To assess the safety of GP IIb/IIIa antagonists tirofiban in patients with ST elevation myocardial infarction (STEMI) during emergency Percutaneous Coronary Intervention (PCI).

Method 120 patients with STEMI during emergency PCI, divided into two groups, tirofiban+PCI group (n=60) and primary PCI group (n=60). The two groups are compared on their major adverse cardiovascular events (MACE) rates which consisted of death, new onset myocardial infarction, persistent myocardial ischeamic state, Cardiac function (1eft ventricular ejection fraction) after operation, compression haemostasia time and adverse drug effect while in hospital.

Result Major adverse cardiovascular events (MACE) rates in tirofiban+PCI group was higher than that of primary PCI group (10% vs 6.7%); Postoperative heart function was better in tirofiban+PCI group than that in primary PCI group (56.97±8.41 vs 54.15±7.11): There was no difference in severe haemorrhage between the two groups.The bleeding event rates were of higher tendency in tirofiban+PCI group. (8.3% vs 3.3%). APTT and compression haemostasia time of tirofiban+PCI group were significant when prolonged (53.97±10.58 vs 32.51±6.31) p<0.05), but no more bleeding and heamatom events occurred during prolongation.

Conclusion GPII b/III a antagonists tirofiban+PCI is a possible safe and effective reperfusion method with STEMI during emergency PCI.

  • Tirofiban
  • ST-elevation myocardial infarction
  • Percutaneous coronary intervention
  • ST elevation myocardial infarction (STEMI)
  • Major adverse cardiovascular events (MACE)
  • Percutaneous Coronary Intervention (PCI)

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.